NASDAQ:TXMD - TherapeuticsMD Stock Price, Price Target & More

$5.71 -0.14 (-2.39 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$5.71
Today's Range$5.68 - $5.85
52-Week Range$3.50 - $7.01
Volume1.20 million shs
Average Volume1.95 million shs
Market Capitalization$1.26 billion
P/E Ratio-15.43
Dividend YieldN/A
Beta1.36

About TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD logoTherapeuticsMD, Inc. is a healthcare company, which focuses on developing and commercializing products for women. Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. The company also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the vitaMedMD and BocaGreenMD brands. TherapeuticsMD was founded by Robert G. Finizio and Brian A. Bernick in 2008 and is headquartered in Boca Raton, FL.

Receive TXMD News and Ratings via Email

Sign-up to receive the latest news and ratings for TXMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:TXMD
CUSIPN/A
Phone561-961-1900

Debt

Debt-to-Equity RatioN/A
Current Ratio10.48%
Quick Ratio10.37%

Price-To-Earnings

Trailing P/E Ratio-15.43
Forward P/E Ratio-14.28
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.78 million
Price / Sales73.64
Cash FlowN/A
Price / CashN/A
Book Value$0.60 per share
Price / Book9.52

Profitability

EPS (Most Recent Fiscal Year)($0.37)
Net Income$-76,920,000.00
Net Margins-458.49%
Return on Equity-63.67%
Return on Assets-57.53%

Miscellaneous

Employees173
Outstanding Shares216,400,000

How to Become a New Pot Stock Millionaire

TherapeuticsMD (NASDAQ:TXMD) Frequently Asked Questions

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD Inc (NASDAQ:TXMD) released its quarterly earnings data on Tuesday, February, 20th. The company reported ($0.10) EPS for the quarter, missing the Zacks' consensus estimate of ($0.09) by $0.01. The firm earned $4.13 million during the quarter, compared to the consensus estimate of $4.66 million. TherapeuticsMD had a negative net margin of 458.49% and a negative return on equity of 63.67%. TherapeuticsMD's quarterly revenue was down 8.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.12) EPS. View TherapeuticsMD's Earnings History.

What price target have analysts set for TXMD?

9 brokerages have issued 12-month price objectives for TherapeuticsMD's stock. Their forecasts range from $6.00 to $28.00. On average, they expect TherapeuticsMD's share price to reach $14.50 in the next year. View Analyst Ratings for TherapeuticsMD.

Are investors shorting TherapeuticsMD?

TherapeuticsMD saw a increase in short interest in the month of March. As of March 29th, there was short interest totalling 57,501,783 shares, an increase of 0.8% from the March 15th total of 57,941,715 shares. Based on an average daily volume of 1,926,644 shares, the days-to-cover ratio is currently 29.8 days. Currently, 33.1% of the company's stock are short sold.

Who are some of TherapeuticsMD's key competitors?

Who are TherapeuticsMD's key executives?

TherapeuticsMD's management team includes the folowing people:
  • Robert G. Finizio, Chief Executive Officer & Director
  • John C. K. Milligan, President & Director
  • Daniel Alan Cartwright, Chief Financial Officer, Treasurer & VP
  • Brian A. Bernick, Director & Chief Clinical Officer
  • Sebastian Mirkin, Chief Medical Officer

Has TherapeuticsMD been receiving favorable news coverage?

Media stories about TXMD stock have been trending somewhat negative this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. TherapeuticsMD earned a news sentiment score of -0.01 on Accern's scale. They also assigned news coverage about the company an impact score of 47.80 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of TherapeuticsMD?

Shares of TXMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $5.71.

How big of a company is TherapeuticsMD?

TherapeuticsMD has a market capitalization of $1.26 billion and generates $16.78 million in revenue each year. The company earns $-76,920,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis. TherapeuticsMD employs 173 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 6800 BROKEN SOUND PARKWAY NW, BOCA RATON FL, 33487. The company can be reached via phone at 561-961-1900 or via email at [email protected]


MarketBeat Community Rating for TherapeuticsMD (TXMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  152 (Vote Outperform)
Underperform Votes:  108 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about TherapeuticsMD and other stocks. Vote "Outperform" if you believe TXMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TXMD will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

TherapeuticsMD (NASDAQ:TXMD) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
9 Wall Street analysts have issued ratings and price targets for TherapeuticsMD in the last 12 months. Their average twelve-month price target is $14.50, suggesting that the stock has a possible upside of 153.94%. The high price target for TXMD is $28.00 and the low price target for TXMD is $6.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.892.892.892.91
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.50$14.50$14.50$16.25
Price Target Upside: 153.94% upside184.31% upside124.81% upside234.36% upside

TherapeuticsMD (NASDAQ:TXMD) Consensus Price Target History

Price Target History for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/21/2018OppenheimerReiterated RatingBuyMediumView Rating Details
3/9/2018Noble FinancialReiterated RatingBuyMediumView Rating Details
1/7/2018Cantor FitzgeraldReiterated RatingBuy$28.00LowView Rating Details
12/20/2017Deutsche BankSet Price TargetBuy$9.00HighView Rating Details
11/6/2017CowenReiterated RatingOutperform$13.00 -> $16.00N/AView Rating Details
9/26/2017Jefferies GroupReiterated RatingBuy$15.00MediumView Rating Details
9/8/2017Morgan StanleyInitiated CoverageEqual Weight$6.00N/AView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$20.00LowView Rating Details
7/11/2017CIBCUpgradeMarket Perform -> OutperformHighView Rating Details
12/6/2016GuggenheimReiterated RatingPositiveN/AView Rating Details
12/4/2016Goldman SachsReiterated RatingBuy$10.50N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

TherapeuticsMD (NASDAQ:TXMD) Earnings History and Estimates Chart

Earnings by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ:TXMD) Earnings Estimates

2018 EPS Consensus Estimate: ($0.43)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.10)($0.08)($0.09)
Q2 20182($0.11)($0.10)($0.11)
Q3 20182($0.12)($0.10)($0.11)
Q4 20182($0.15)($0.09)($0.12)

TherapeuticsMD (NASDAQ TXMD) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018Q4 2017($0.09)($0.10)$4.66 million$4.13 millionViewListenView Earnings Details
11/6/2017Q3 2017($0.10)($0.0710)$5.36 million$4.42 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.11)($0.10)$4.91 million$4.25 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.11)($0.11)$5.29 million$3.99 millionViewN/AView Earnings Details
2/23/2017Q416($0.12)($0.12)$5.91 million$4.49 millionViewListenView Earnings Details
11/3/2016Q316($0.11)($0.13)$5.76 million$5.50 millionViewN/AView Earnings Details
8/4/2016Q216($0.10)($0.11)$5.63 million$4.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.09)($0.11)$5.73 million$4.93 millionViewN/AView Earnings Details
2/25/2016Q415($0.10)($0.10)$5.33 million$5.63 millionViewListenView Earnings Details
11/4/2015Q315($0.12)($0.11)$5.01 million$5.19 millionViewN/AView Earnings Details
8/6/2015Q215($0.11)($0.16)$4.65 million$4.80 millionViewListenView Earnings Details
5/5/2015($0.10)($0.13)$4.34 million$4.48 millionViewN/AView Earnings Details
3/10/2015Q414($0.09)($0.10)$2.86 million$4.26 millionViewN/AView Earnings Details
11/6/2014Q3 14($0.08)($0.12)$3.90 million$4.19 millionViewN/AView Earnings Details
8/6/2014Q2 2014($0.08)($0.07)$3.12 million$3.75 millionViewN/AView Earnings Details
5/6/2014Q1 14($0.06)($0.06)$3.08 million$2.80 millionViewN/AView Earnings Details
3/3/2014Q213($0.06)($0.06)$2.72 million$2.90 millionViewN/AView Earnings Details
11/4/2013Q3 2013($0.04)($0.06)$2.55 million$2.30 millionViewN/AView Earnings Details
8/6/2013Q2 2013($0.06)($0.05)$1.51 million$2.08 millionViewN/AView Earnings Details
5/8/2013Q113($0.06)($0.06)$1.32 million$1.50 millionViewN/AView Earnings Details
3/12/2013Q4 2012($0.06)($0.05)ViewN/AView Earnings Details
11/13/2012Q3 2012($0.04)($0.04)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

TherapeuticsMD (NASDAQ:TXMD) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

TherapeuticsMD (NASDAQ TXMD) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 23.92%
Institutional Ownership Percentage: 73.31%
Insider Trading History for TherapeuticsMD (NASDAQ:TXMD)
Institutional Ownership by Quarter for TherapeuticsMD (NASDAQ:TXMD)

TherapeuticsMD (NASDAQ TXMD) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/8/2017Tommy G ThompsonDirectorBuy5,000$6.21$31,050.003,555View SEC Filing  
8/30/2017Tommy G ThompsonDirectorBuy5,000$5.99$29,950.003,555View SEC Filing  
3/11/2016Cooper C CollinsDirectorBuy16,000$6.23$99,680.0036,000View SEC Filing  
8/25/2015Angus C RussellDirectorBuy13,500$5.98$80,730.0048,500View SEC Filing  
6/8/2015Mitchell KrassanEVPSell30,000$8.18$245,400.00View SEC Filing  
5/12/2015Angus C RussellDirectorBuy35,000$6.15$215,250.00View SEC Filing  
5/11/2015Tommy G ThompsonChairmanBuy6,000$6.09$36,540.00View SEC Filing  
5/8/2015J Martin CarrollDirectorBuy10,000$6.11$61,100.00View SEC Filing  
11/21/2014Daniel A CartwrightCFOSell40,000$3.91$156,400.00View SEC Filing  
9/4/2014Tommy G ThompsonDirectorBuy1,757$5.44$9,558.08View SEC Filing  
6/5/2014Cooper C CollinsDirectorBuy20,000$3.84$76,800.00View SEC Filing  
5/9/2014Robert Lapenta, Jr.DirectorBuy5,000$3.66$18,300.0010,000View SEC Filing  
5/8/2014Tommy ThompsonDirectorBuy14,000$3.57$49,980.00View SEC Filing  
3/26/2014Brian BernickDirectorSell421,268$6.70$2,822,495.60297,000View SEC Filing  
3/26/2014John C.K. Iv MilliganInsiderSell353,412$6.70$2,367,860.401,722,419View SEC Filing  
3/26/2014Robert FinizioCEOSell982,053$6.70$6,579,755.1021,029,533View SEC Filing  
3/10/2014Mitchell KrassanEVPSell7,500$7.73$57,975.00View SEC Filing  
2/26/2014John C.K. Iv MilliganPresidentSell25,000$6.31$157,750.006,318,018View SEC Filing  
2/21/2014Robert FinizioCEOSell50,000$6.17$308,500.0022,011,586View SEC Filing  
2/12/2014Brian BernickDirectorSell31,250$6.16$192,500.00View SEC Filing  
1/30/2014John C.K. Iv MilliganInsiderSell25,000$6.16$154,000.006,343,018View SEC Filing  
1/23/2014Robert G FinizioCEOSell50,000$5.70$285,000.00View SEC Filing  
1/13/2014Mitchell KrassanEVPSell7,500$5.73$42,975.00View SEC Filing  
1/8/2014Brian BernickDirectorSell31,250$5.13$160,312.50View SEC Filing  
8/26/2013Brian BernickInsiderSell1,600,000$1.55$2,480,000.00View SEC Filing  
8/26/2013Jules A MusingDirectorBuy5,282$2.15$11,356.30View SEC Filing  
6/14/2013Cooper C CollinsDirectorSell2,631,579$1.75$4,605,263.25View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

TherapeuticsMD (NASDAQ TXMD) News Headlines

Source:
DateHeadline
TherapeuticsMD (TXMD) Rating Lowered to Sell at Zacks Investment ResearchTherapeuticsMD (TXMD) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 2:28 PM
 Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Post Quarterly Sales of $4.10 Million Analysts Anticipate TherapeuticsMD Inc (TXMD) Will Post Quarterly Sales of $4.10 Million
www.americanbankingnews.com - April 16 at 2:19 AM
TherapeuticsMD Inc (TXMD) Expected to Post Earnings of -$0.10 Per ShareTherapeuticsMD Inc (TXMD) Expected to Post Earnings of -$0.10 Per Share
www.americanbankingnews.com - April 14 at 7:18 PM
BRIEF-TherapeuticsMD Enters Into Negotiations With US FDA For TX-004HRBRIEF-TherapeuticsMD Enters Into Negotiations With US FDA For TX-004HR
www.reuters.com - April 13 at 8:20 AM
TherapeuticsMD Inc (TXMD) Given Consensus Rating of "Buy" by BrokeragesTherapeuticsMD Inc (TXMD) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 12 at 3:34 AM
TherapeuticsMD (TXMD) Upgraded to "Hold" by Zacks Investment ResearchTherapeuticsMD (TXMD) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - April 11 at 1:23 PM
TherapeuticsMD Enters Into Label Negotiations for TX-004HRTherapeuticsMD Enters Into Label Negotiations for TX-004HR
finance.yahoo.com - April 11 at 8:32 AM
TherapeuticsMD (TXMD) PT Set at $10.00 by Deutsche BankTherapeuticsMD (TXMD) PT Set at $10.00 by Deutsche Bank
www.americanbankingnews.com - April 9 at 10:52 PM
TherapeuticsMD (TXMD) PT Set at $10.00 by OppenheimerTherapeuticsMD (TXMD) PT Set at $10.00 by Oppenheimer
www.americanbankingnews.com - April 6 at 10:22 PM
TherapeuticsMD (TXMD) Stock Rating Upgraded by BidaskClubTherapeuticsMD (TXMD) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 5 at 6:21 PM
TherapeuticsMD (TXMD) Upgraded at ValuEngineTherapeuticsMD (TXMD) Upgraded at ValuEngine
www.americanbankingnews.com - April 2 at 10:52 PM
TherapeuticsMD Announces Expansion of Board of DirectorsTherapeuticsMD Announces Expansion of Board of Directors
finance.yahoo.com - April 2 at 8:41 AM
TherapeuticsMD (TXMD) Upgraded to Sell by BidaskClubTherapeuticsMD (TXMD) Upgraded to Sell by BidaskClub
www.americanbankingnews.com - March 30 at 10:02 PM
TherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.21 MillionTherapeuticsMD Inc (TXMD) Expected to Announce Quarterly Sales of $4.21 Million
www.americanbankingnews.com - March 30 at 1:52 AM
TherapeuticsMD (TXMD) Receives Buy Rating from OppenheimerTherapeuticsMD (TXMD) Receives Buy Rating from Oppenheimer
www.americanbankingnews.com - March 21 at 7:48 PM
Quotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and ZogenixQuotidian Technical Highlights on Selected Drug Makers Stocks -- Sanofi, Shire, TherapeuticsMD, and Zogenix
www.bizjournals.com - March 19 at 5:17 PM
TherapeuticsMD, New PipelineNDA Development, Analysts Target and PDUFA DateTherapeuticsMD, New PipelineNDA Development, Analysts Target and PDUFA Date
finance.yahoo.com - March 19 at 8:24 AM
TherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from BrokeragesTherapeuticsMD Inc (TXMD) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - March 18 at 3:42 AM
 Brokerages Expect TherapeuticsMD Inc (TXMD) to Post -$0.09 EPS Brokerages Expect TherapeuticsMD Inc (TXMD) to Post -$0.09 EPS
www.americanbankingnews.com - March 11 at 2:12 PM
TherapeuticsMD Inc (TXMD) Short Interest UpdateTherapeuticsMD Inc (TXMD) Short Interest Update
www.americanbankingnews.com - March 11 at 1:58 AM
The 5 Most Shorted Nasdaq StocksThe 5 Most Shorted Nasdaq Stocks
www.msn.com - March 10 at 6:23 PM
TherapeuticsMD (TXMD) Given "Buy" Rating at Noble FinancialTherapeuticsMD (TXMD) Given "Buy" Rating at Noble Financial
www.americanbankingnews.com - March 10 at 5:09 PM
Therapeutics Wins FDA Nod, Stocks Dont BudgeTherapeutics Wins FDA Nod, Stocks Don't Budge
www.baystreet.ca - March 9 at 6:49 PM
TherapeuticsMD (TXMD) Given a $10.00 Price Target at OppenheimerTherapeuticsMD (TXMD) Given a $10.00 Price Target at Oppenheimer
www.americanbankingnews.com - March 9 at 2:44 PM
TherapeuticsMD (TXMD) FDA Accepts TX-001HR NDA; 10/28/18 ... - StreetInsider.comTherapeuticsMD (TXMD) FDA Accepts TX-001HR NDA; 10/28/18 ... - StreetInsider.com
www.streetinsider.com - March 9 at 8:21 AM
Today’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and TherapeuticsMDToday’s Research Reports on Stocks to Watch: AcelRx Pharmaceuticals and TherapeuticsMD
finance.yahoo.com - March 9 at 8:21 AM
BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001HrBRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr
www.reuters.com - March 8 at 6:41 PM
TherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HRTherapeuticsMD Announces FDA Acceptance of New Drug Application (NDA) and Prescription Drug User Fee Act (PDUFA) Date for TX-001HR
finance.yahoo.com - March 8 at 6:41 PM
TherapeuticsMD to Present at Two Upcoming Investor Conferences ... - Business Wire (press release)TherapeuticsMD to Present at Two Upcoming Investor Conferences ... - Business Wire (press release)
www.businesswire.com - March 7 at 8:19 AM
Commit To Purchase TherapeuticsMD At $3, Earn 17.2% Annualized Using Options - NasdaqCommit To Purchase TherapeuticsMD At $3, Earn 17.2% Annualized Using Options - Nasdaq
www.nasdaq.com - March 7 at 8:19 AM
TherapeuticsMD (TXMD) Rating Lowered to Strong Sell at ValuEngineTherapeuticsMD (TXMD) Rating Lowered to Strong Sell at ValuEngine
www.americanbankingnews.com - March 3 at 4:14 PM
Short Interest in TherapeuticsMD Inc (TXMD) Rises By 4.2%Short Interest in TherapeuticsMD Inc (TXMD) Rises By 4.2%
www.americanbankingnews.com - March 1 at 2:40 AM
FY2018 EPS Estimates for TherapeuticsMD Inc Raised by Analyst (TXMD)FY2018 EPS Estimates for TherapeuticsMD Inc Raised by Analyst (TXMD)
www.americanbankingnews.com - February 26 at 5:28 AM
Oppenheimer Analysts Cut Earnings Estimates for TherapeuticsMD Inc (TXMD)Oppenheimer Analysts Cut Earnings Estimates for TherapeuticsMD Inc (TXMD)
www.americanbankingnews.com - February 26 at 1:28 AM
TherapeuticsMD (TXMD) Stock Rating Lowered by BidaskClubTherapeuticsMD (TXMD) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 24 at 9:48 PM
Zacks: Analysts Expect TherapeuticsMD Inc (TXMD) Will Announce Quarterly Sales of $4.22 MillionZacks: Analysts Expect TherapeuticsMD Inc (TXMD) Will Announce Quarterly Sales of $4.22 Million
www.americanbankingnews.com - February 24 at 2:12 AM
TherapeuticsMDs (TXMD) "Buy" Rating Reiterated at Noble FinancialTherapeuticsMD's (TXMD) "Buy" Rating Reiterated at Noble Financial
www.americanbankingnews.com - February 23 at 6:08 PM
TherapeuticsMD Inc (TXMD) Files 10-K for the Fiscal Year Ended on December 31, 2017TherapeuticsMD Inc (TXMD) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 23 at 5:57 PM
FY2020 EPS Estimates for TherapeuticsMD Inc (TXMD) Increased by AnalystFY2020 EPS Estimates for TherapeuticsMD Inc (TXMD) Increased by Analyst
www.americanbankingnews.com - February 23 at 4:40 PM
FY2020 EPS Estimates for TherapeuticsMD Inc Reduced by Analyst (TXMD)FY2020 EPS Estimates for TherapeuticsMD Inc Reduced by Analyst (TXMD)
www.americanbankingnews.com - February 23 at 4:40 PM
TherapeuticsMD Inc (TXMD) Forecasted to Earn FY2019 Earnings of $0.24 Per ShareTherapeuticsMD Inc (TXMD) Forecasted to Earn FY2019 Earnings of $0.24 Per Share
www.americanbankingnews.com - February 23 at 3:34 PM
TherapeuticsMD: Debt Financing Delay - Seeking AlphaTherapeuticsMD: Debt Financing Delay - Seeking Alpha
seekingalpha.com - February 23 at 8:23 AM
Wired News - Merck to Acquire Australia-based Viralytics to Broaden Immuno-Oncology PortfolioWired News - Merck to Acquire Australia-based Viralytics to Broaden Immuno-Oncology Portfolio
finance.yahoo.com - February 23 at 8:23 AM
Jefferies Group Comments on TherapeuticsMD Incs Q1 2018 Earnings (TXMD)Jefferies Group Comments on TherapeuticsMD Inc's Q1 2018 Earnings (TXMD)
www.americanbankingnews.com - February 22 at 7:06 AM
TherapeuticsMD (TXMD) Given a $10.00 Price Target by Oppenheimer AnalystsTherapeuticsMD (TXMD) Given a $10.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - February 21 at 2:04 PM
TherapeuticsMD (TXMD) Issues  Earnings ResultsTherapeuticsMD (TXMD) Issues Earnings Results
www.americanbankingnews.com - February 21 at 12:10 PM
TherapeuticsMDs (TXMD) CEO Robert Finizio on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaTherapeuticsMD's (TXMD) CEO Robert Finizio on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - February 21 at 8:23 AM
TherapeuticsMD Inc (TXMD) Given Average Rating of "Buy" by AnalystsTherapeuticsMD Inc (TXMD) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 21 at 3:34 AM
TherapeuticsMD Q4 Earnings PreviewTherapeuticsMD Q4 Earnings Preview
finance.yahoo.com - February 20 at 5:45 PM
TherapeuticsMD reports 4Q lossTherapeuticsMD reports 4Q loss
finance.yahoo.com - February 20 at 5:45 PM

SEC Filings

TherapeuticsMD (NASDAQ:TXMD) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

TherapeuticsMD (NASDAQ:TXMD) Income Statement, Balance Sheet and Cash Flow Statement

Chart

TherapeuticsMD (NASDAQ TXMD) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.